Gynaecology

Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference

Retrieved on: 
Thursday, February 22, 2024
Gynaecology, Conference

AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024.

Key Points: 
  • AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024.
  • Management will be available for one-on-one meetings with investors who are registered for the conference.

Ovation Fertility Welcomes Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), as Cincinnati Lab Director

Retrieved on: 
Tuesday, February 20, 2024
Gynaecology, OBGYN, Doctor of Philosophy, Suite, Research, Physician, Wright, IVF, ELD, ABB, Cryopreservation, Andrology, Obstetrics, University, Jan Vansina, Patient, FIRST, Knowledge, Diagnosis, Laboratory, Partnership, Medical device

Nashville, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), has joined the Ovation® Fertility team as laboratory director of Ovation Fertility Cincinnati, effective February 1, 2024.

Key Points: 
  • Nashville, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pradeep Warikoo, PhD, HCLD, ELD, CC (ABB), has joined the Ovation® Fertility team as laboratory director of Ovation Fertility Cincinnati, effective February 1, 2024.
  • Dr. Warikoo comes to Ovation from the Bethesda Fertility Center Reproductive Study Lab in Cincinnati, where he has served as scientific director for more than 25 years.
  • “Ovation’s expansion in the Cincinnati area involves a close partnership with our partner physicians at the Institute for Reproductive Health, which combined with Bethesda Fertility Center effective February 1,” says Conor Beardsley, President of Ovation Fertility.
  • He is board certified by the American Board of Bioanalysis as a High Complexity Laboratory Director, Embryology Laboratory Director and Clinical Consultant.

PanTheryx® Welcomes Menopause Specialist, Jaime Seeman, M.D., OB-GYN to its Scientific Advisory Board

Retrieved on: 
Thursday, March 7, 2024
Health, Consumer, Women, Fitness & Nutrition, General Health, Vitamins, Supplements, Private practice, Woman, System, Obstetrics, Multimedia, RDN, University, American Nutrition Association, Nebraska Medicine, Skin, Gynaecology, Probiotic, Outline of health sciences, Menopause, Alternative medicine, Mid-City, Physical fitness, North American Menopause Society, Dietary supplement

and OB-GYN to its esteemed Scientific Advisory Board.

Key Points: 
  • and OB-GYN to its esteemed Scientific Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20240307019894/en/
    "We are delighted to welcome Dr. Jaime Seeman as a new member of our Scientific Advisory Board.
  • "I am honored to join the respected group of experts on PanTheryx’s Scientific Advisory Board.
  • ; and Mia Syn, MS, RDN, on PanTheryx's Scientific Advisory Board, each committed to advancing the company's mission to bring cutting-edge research, and innovative products to consumers.

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

Retrieved on: 
Wednesday, March 6, 2024
Health, FDA, Diabetes, Other Science, Research, Science, Biotechnology, Urology, Regenerative medicine, Immunotherapy, Food, Regulatory T cell, Elective surgery, Gynaecology, Endocrinology, DNP, Transplant, Immunosuppression, CCRP, Patient, Autoimmunity, Drug, Pharmaceutical industry

Timothy Warbington, CEO of Creative Medical Technology Holdings, stated, "The FDA's Orphan Drug Designation for CELZ-101 underscores our commitment to developing groundbreaking therapies.

Key Points: 
  • Timothy Warbington, CEO of Creative Medical Technology Holdings, stated, "The FDA's Orphan Drug Designation for CELZ-101 underscores our commitment to developing groundbreaking therapies.
  • “The Orphan Drug Designation by the FDA highlights CELZ-101's potential to meet a significant unmet need in the prevention of allograft rejection during pancreatic islet cell transplantation which was recently approved by the FDA.
  • Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is dedicated to progressing CELZ-101 through the necessary regulatory pathways, with the goal of transforming the therapeutic landscape for patients in need of islet transplantation.
  • This achievement underscores the company's dedication to leveraging the natural regenerative capabilities of the human body to create lasting health solutions.

ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, FDA, AIDS, Health, Training, Pharmaceutical, Other Education, Other Philanthropy, Philanthropy, Research, Infectious Diseases, Education, Science, Clinical Trials, Acquisition, Pre-exposure prophylaxis, Pfizer, Incidence, Shionogi, Woman, Medicine, Fungal infection, GSK, CROI, HIV Medicine, Notifiable disease, Emergency medicine, Dawn, Conference, Gynaecology, Mentorship, Preceptor, Patient, MPH, ViiV Healthcare, HIV, Obstetrics, American Academy, Pharmaceutical industry

Today, ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine (AAHIVM) jointly announced the launch of The Dr.

Key Points: 
  • Today, ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine (AAHIVM) jointly announced the launch of The Dr.
  • Dawn K. Smith HIV Prevention Clinical Fellowship.
  • The fellowship will provide comprehensive HIV training to non-infectious disease clinicians serving communities disproportionately affected by HIV.
  • Dawn K. Smith HIV Prevention Clinical Fellowship, experienced HIV clinicians will provide that training in priority populations and areas, with a special emphasis on pre-exposure prophylaxis (PrEP).”
    The Dr.

Clinical Chemistry Analyzers Market, Size, Global Forecast Report 2024-2030 Featuring Thermo Fisher Scientific, Abbott Laboratories, Siemens, Danaher, Johnson & Johnson, Sysmex ADR, HORIBA, Hitachi - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024
Science, Health, Research, Other Health, Diabetes, Incidence, Sickness, BMP, Intelligence, IDF, Immunochemistry, Calcium, World Games, Gynaecology, Electrolyte, Endocrinology, Biomarker, Disease, Glucose, Diagnosis, Basic metabolic panel, WHO, DSM-IV codes, Cancer, Medical device

The "Clinical Chemistry Analyzers Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Clinical Chemistry Analyzers Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Technological improvements in clinical chemistry analyzers have enabled broader testing skills and early sickness detection, particularly in specialized sectors like cancer, gynecology, and endocrinology.
  • These essential chemical substances enable clinical chemistry analyzers to detect and measure various biomarkers, making them indispensable in the healthcare industry.
  • U.S.-based manufacturers continually introduce state-of-the-art clinical chemistry analyzers that cater to the evolving requirements of healthcare providers.

Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women's Health and Femtech

Retrieved on: 
Wednesday, February 28, 2024
Health, Venture Capital, Neurology, Finance, Consumer, Other Health, Professional Services, Oncology, Other Science, Mental Health, General Health, Science, Women, Cardiology, Cervical cancer, Mental health, Call, Investment, Physician, Partnership, Femtech, Venture capital, Gynaecology, Endocrinology, Ecosystem, SAFE, Patient, Intellectual property, Diagnosis, HTH, Community, Wi-Fi Direct, Gastroenterology, Pharmaceutical industry

Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences.

Key Points: 
  • Zcube - Zambon Research Venture announces the fifth edition of Open Accelerator, the international acceleration program for high-potential innovative startups in the field of life sciences.
  • Starting this year, the program will focus on the femtech sector and will feature a new format.
  • The targeted therapeutic areas include gynecology, cardiovascular health, oncology, sexual health, endocrinology, gastroenterology, nutrition, autoimmune disorders, mental health, neurology, reproductive health, and more.
  • The Call for application will open on Friday, March 8, 2024, on the International Women's Day, and will remain open until June 16.

Virtual Incision Receives FDA Authorization for the MIRA Surgical System as the First Miniaturized Robotic-Assisted Surgery Device

Retrieved on: 
Saturday, February 24, 2024
Technology, Surgery, Medical Devices, FDA, Hospitals, Health Technology, Health, Robotics, Artificial Intelligence, MIRA, Miniaturization, Food, Surgeon, IDE, General surgery, MIS, Gynaecology, Colectomy, Patient, Operating, Trial of the century, 3D printing

Virtual Incision Corporation announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization of the MIRA™ Surgical System (MIRA), the world’s first miniaturized robotic-assisted surgery (miniRAS) device, for use in adults undergoing colectomy procedures.

Key Points: 
  • Virtual Incision Corporation announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization of the MIRA™ Surgical System (MIRA), the world’s first miniaturized robotic-assisted surgery (miniRAS) device, for use in adults undergoing colectomy procedures.
  • FDA authorization was based in part on findings from the company’s U.S. Investigational Device Exemption (IDE) clinical study.
  • The announcement was made by Virtual Incision’s president and chief executive officer, John Murphy, at the SAGES 5th Annual Next Big Thing Innovation Weekend in Houston.
  • “Today marks a turning point in surgical robotics as we have hit a significant milestone in making miniaturized robotic surgery a reality,” said John Murphy.

Hammes completes Silicon Valley Surgery Center in Campbell, California

Retrieved on: 
Tuesday, February 27, 2024
Urology, Senior, Physician, Silicon, General surgery, Gynaecology, Pain management, Operating, HCA Healthcare, Otorhinolaryngology, Hand, Podiatry, Gastroenterology, Obstetrics, Hospital

MILWAUKEE, Feb. 27, 2024 /PRNewswire-PRWeb/ -- Hammes, a nationally recognized leader in healthcare development, completed the development of a new ambulatory surgery center located at 2605 South Winchester Boulevard in Campbell, California. Silicon Valley Surgery Center is a joint venture between Surgery Ventures, powered by HCA Healthcare, and more than 50 multi-specialty physicians.

Key Points: 
  • Silicon Valley Surgery Center is a joint venture between Surgery Ventures, powered by HCA Healthcare, and more than 50 multi-specialty physicians.
  • We are proud to have supported the Silicon Valley Surgery Center surgeons and medical staff with a seamless transition from multiple locations to this new, conveniently located, state-of-the-art center.
  • The Silicon Valley Surgery Center team relocated from existing locations to the new, 24,000-square-foot, state-of-the-art surgery center at the end of 2023.
  • "We are proud to have supported the Silicon Valley Surgery Center surgeons and medical staff with a seamless transition from multiple locations to this new, conveniently located, state-of-the-art center," said Stephen Buckeridge, Senior Vice President of Hammes Partners.

Virtual Incision Receives FDA Authorization for the First Miniaturized Robotic-Assisted Surgery Device

Retrieved on: 
Tuesday, February 27, 2024
MIRA, MD, FDA, Thought, IDE, MBA, General surgery, Gynaecology, Capital, Medicine, Hand, Trial of the century, Incision, Robotics, Medical device

GRAND RAPIDS, Mich., Feb. 27, 2024 /PRNewswire/ -- Virtual Incision , a cultivate(MD) portfolio company , has been granted marketing authorization of the MIRA™ Surgical System (MIRA) from the FDA.

Key Points: 
  • GRAND RAPIDS, Mich., Feb. 27, 2024 /PRNewswire/ -- Virtual Incision , a cultivate(MD) portfolio company , has been granted marketing authorization of the MIRA™ Surgical System (MIRA) from the FDA.
  • This marks a significant milestone as MIRA becomes the first miniaturized robotic-assisted surgery device in the world approved for adult colectomy procedures.
  • FDA authorization was based in part on findings from the company's U.S. Investigational Device Exemption (IDE) clinical study.
  • With FDA authorization in hand, Virtual Incision is set to initiate MIRA's commercial rollout in select centers in the United States.